Table 2.
Metabolite | p-Value a | VIP b | Fold Change (vs. Control) |
||
---|---|---|---|---|---|
GL | GH | ||||
Kidney | uracil | 1.83 × 102 | 0.94 | −1.14 | −1.19 |
glutathione, oxidized | 5.64 × 104 | 1.40 | −2.78 | −2.87 | |
succinyladenosine | 1.23 × 102 | 0.95 | −1.50 | −1.00 | |
riboflavin | 2.00 × 103 | 1.21 | −1.01 | 1.35 | |
leucyl histidine | 2.51 × 105 | 1.45 | −1.02 | −1.50 | |
stearoylcarnitine | 2.70 × 102 | 0.96 | 1.47 | 1.60 | |
Liver | carnitine | 3.30 × 102 | 1.10 | 1.06 | 1.46 |
LPE(C20:4) | 2.40 × 103 | 2.54 | 1.16 | 1.57 | |
LPC(C18:1) | 2.24 × 102 | 1.58 | 1.21 | −1.33 | |
Plasma | LPE(C18:3) | 7.05 × 104 | 0.69 | −2.18 | −2.66 |
LPC(C16:1) | 1.04 × 104 | 0.55 | −2.19 | −3.97 | |
LPC(C20:4) | 7.56 × 105 | 1.00 | −2.20 | −4.50 | |
LPC(C18:2) | 1.46 × 104 | 2.48 | −2.16 | −4.62 | |
LPC(C18:3) | 1.23 × 103 | 0.17 | −2.32 | −3.39 | |
LPC(C16:0) | 4.12 × 105 | 3.28 | −2.15 | −3.93 | |
LPC(C18:1) | 2.12 × 104 | 1.88 | −2.76 | −6.58 | |
LPC(C17:0) | 3.55 × 105 | 0.49 | −3.20 | −7.34 | |
LPC(C18:0) | 5.20 × 105 | 2.41 | −3.03 | −5.90 | |
Estradiol-3-glucuronate | 1.08 × 102 | 0.96 | 1.10 | −1.03 | |
estrone-3-hemisuccinate | 9.92 × 103 | 1.00 | 1.47 | −1.30 | |
11α-hydroxyestradiol | 2.62 × 1023 | 0.79 | 1.13 | 1.10 | |
21α-hydroxyprogesterone | 3.87 × 103 | 1.02 | 1.53 | −1.08 | |
Urine | 27-hydroxycholesterol | 1.78 × 102 | 0.94 | −1.25 | 1.19 |
metandienone | 3.76 × 102 | 0.78 | 1.26 | 1.00 | |
2-hydroxyestrone-1+4-N-acetylcysteine | 3.16 × 102 | 0.90 | 1.98 | 2.13 | |
6-dehydroestradiol diacetate | 2.71 × 102 | 0.95 | 1.13 | 1.33 | |
estriol-16,17-diacetate | 2.60 × 102 | 0.82 | 2.14 | −1.01 | |
2,3-dimethoxyestradiol | 3.57 × 102 | 0.85 | 1.48 | −1.62 | |
5-androstenediol | 4.17 × 102 | 0.86 | −1.42 | −1.43 | |
11β-hydroxyestradiol derivatives | 7.45 × 102 | 1.86 | 6.75 | 6.67 |
a Variable importance in the projection (VIP) values were determined by PLS-DA. b p-Value were analyzed by ANOVA with Duncan’s test.